Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 24 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.59 Insider Own9.18% Shs Outstand49.10M Perf Week-9.61%
Market Cap21.46M Forward P/E- EPS next Y-0.47 Insider Trans6.43% Shs Float45.32M Perf Month-2.27%
Income-28.96M PEG- EPS next Q- Inst Own8.32% Short Float1.09% Perf Quarter7.39%
Sales0.20M P/S107.29 EPS this Y10.00% Inst Trans-3.63% Short Ratio2.11 Perf Half Y-1.65%
Book/sh0.19 P/B2.21 EPS next Y12.96% ROA-64.84% Short Interest0.49M Perf Year-20.37%
Cash/sh0.26 P/C1.64 EPS next 5Y25.00% ROE-118.94% 52W Range0.32 - 0.75 Perf YTD-2.25%
Dividend Est.- P/FCF- EPS past 5Y42.86% ROI-269.94% 52W High-42.57% Beta-0.12
Dividend TTM- Quick Ratio1.68 Sales past 5Y-2.98% Gross Margin-62.38% 52W Low34.33% ATR (14)0.05
Dividend Ex-Date- Current Ratio1.68 EPS Y/Y TTM-46.75% Oper. Margin-15793.56% RSI (14)44.81 Volatility13.59% 12.01%
Employees26 Debt/Eq0.07 Sales Y/Y TTM44.29% Profit Margin-14337.62% Recom1.00 Target Price2.00
Option/ShortNo / Yes LT Debt/Eq0.05 EPS Q/Q-180.50% Payout- Rel Volume0.68 Prev Close0.43
Sales Surprise69.86% EPS Surprise-116.67% Sales Q/Q16.07% EarningsApr 02 BMO Avg Volume232.87K Price0.43
SMA20-11.81% SMA50-0.26% SMA200-13.45% Trades Volume158,065 Change1.06%
Apr-18-24 08:45AM
Apr-15-24 08:55AM
Apr-11-24 11:00AM
Apr-10-24 08:21AM
Apr-02-24 07:30AM
08:05AM Loading…
Mar-28-24 08:05AM
Mar-26-24 09:05AM
Mar-25-24 09:05AM
Mar-22-24 08:55AM
Mar-20-24 09:25AM
Mar-15-24 08:45AM
Mar-07-24 08:45AM
Feb-29-24 08:45AM
Feb-14-24 08:55AM
Feb-08-24 08:50AM
09:10AM Loading…
Jan-24-24 09:10AM
Jan-22-24 08:55AM
Jan-10-24 08:45AM
Jan-05-24 01:32PM
Jan-03-24 04:05PM
Dec-29-23 08:00AM
Nov-28-23 04:30PM
Nov-27-23 09:00PM
Nov-21-23 12:00PM
Nov-16-23 08:45AM
Nov-15-23 07:30AM
Nov-14-23 10:00AM
Nov-09-23 08:05AM
Nov-08-23 08:45AM
Nov-06-23 09:25AM
08:55AM Loading…
Oct-30-23 08:55AM
Oct-17-23 08:45AM
Sep-22-23 09:05AM
Sep-11-23 01:00PM
Sep-05-23 09:05AM
Aug-23-23 08:00AM
Aug-15-23 06:45AM
Aug-09-23 09:05AM
Aug-08-23 08:05AM
Jul-18-23 07:30PM
Jul-10-23 08:05AM
Jul-05-23 08:35AM
Jun-27-23 11:16AM
Jun-14-23 08:45AM
Jun-12-23 08:45AM
Jun-07-23 07:11PM
May-15-23 08:45AM
May-09-23 08:50AM
Apr-20-23 03:56PM
Apr-12-23 08:35AM
Apr-10-23 07:30AM
Apr-04-23 08:45AM
Apr-03-23 06:30AM
Mar-30-23 08:45AM
Mar-27-23 09:05AM
Mar-16-23 08:45AM
Mar-08-23 08:45AM
Mar-06-23 08:45AM
Feb-28-23 08:45AM
Feb-17-23 08:55AM
Jan-17-23 08:45AM
Jan-11-23 01:00PM
Jan-09-23 08:05AM
Jan-05-23 08:45AM
Dec-12-22 09:00AM
Dec-08-22 08:05AM
Dec-02-22 10:45AM
Nov-15-22 07:00AM
Nov-14-22 07:00AM
Nov-09-22 09:00AM
Nov-03-22 12:34PM
Nov-02-22 07:05AM
Nov-01-22 05:19PM
Oct-31-22 07:30AM
Oct-26-22 05:12PM
Oct-24-22 08:30AM
Oct-13-22 10:32AM
Oct-12-22 04:32PM
Sep-21-22 08:45AM
Sep-19-22 08:05AM
Sep-07-22 07:25AM
Sep-06-22 07:30AM
Aug-30-22 07:30AM
Aug-18-22 09:05AM
Aug-16-22 04:05PM
Aug-15-22 04:05PM
Jul-28-22 09:10AM
Jul-21-22 12:26PM
Jul-20-22 08:05AM
Jul-18-22 08:00AM
Jul-14-22 08:05AM
Jun-21-22 08:35AM
Jun-13-22 08:05AM
AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BRYAN NANCYDirectorMar 21 '24Buy0.3938,46215,00038,462Mar 22 01:30 PM
APPELROUTH STEWARTDirectorMar 15 '24Buy0.3390,91030,000239,765Mar 18 03:01 PM
Equels Thomas KCEO & PresidentMar 15 '24Buy0.3375,75825,000716,455Mar 18 03:01 PM
Rodino Peter W IIICOO, Secretary, Gen. CounselMar 15 '24Buy0.3337,87912,500181,718Mar 18 03:01 PM
Equels Thomas KCEO & PresidentNov 27 '23Buy0.4433,86115,000640,697Nov 27 12:56 PM
Equels Thomas KCEO & PresidentSep 29 '23Buy0.4422,67610,000606,836Sep 29 03:29 PM
Equels Thomas KCEO & PresidentAug 25 '23Buy0.678,2225,501584,160Aug 25 02:26 PM
Equels Thomas KCEO & PresidentAug 24 '23Buy0.6714,99310,000575,938Aug 24 01:52 PM
Equels Thomas KCEO & PresidentJul 17 '23Buy0.5916,95010,000560,945Jul 17 07:20 PM